- Arthur Hayes buys stake in a stem cell therapy company and secures a board position, according to a Bloomberg report.
- The move follows Hayes’s presidential pardon in March 2025, when he was convicted for insufficient AML controls at BitMex.
- “I want to live as long as possible, as healthy as possible,” Hayes stated.
After dabbling in cryptocurrencies for a long time, BitMex co-founder Arthur Hayes has pivoted toward the wellness frontier. Hayes has taken a substantial ownership stake and joined the board of a stem cell therapy company operating clinics in Mexico and Bangkok, a Bloomberg report suggested.
Hayes did not disclose the name of the company; however, he revealed that he himself has been a regular patient for over a year, undergoing stem cell infusions aimed at lengthening his healthspan.“I want to live as long as possible, as healthy as possible,” he told Bloomberg. He has been vocal about the growing global trend of relaxed stem cell regulations.
The company is in the midst of a rebranding exercise, but its presence in Latin America and Southeast Asia means that Hayes could take advantage of their more relaxed health regulations. It is known that Hayes used to live in Singapore and spend at least 3 months a year skiing in Japan.
In March, Trump granted a pardon to Hayes, Benjamin Delo, and Samuel Reed, the three founders of BitMEX, which used to be the biggest crypto derivatives exchange. Back in 2020, they were charged for breaking U.S. banking laws and admitted guilt in 2022. Each of them paid $10 million and got probation.
Hayes told Bloomberg that the pardon didn’t really change his career. He hasn’t left crypto behind; his family office, Maelstrom, still supports Bitcoin projects and helps companies manage digital assets.
Also read: Arthur Hayes slams stablecoin IPO craze as a ‘bubble’
Hayes follows in the footsteps of other crypto luminaries eyeing life-extension science. Vitalik Buterin has donated tens of millions to longevity-focused institutions like the SENS Research Foundation, and Coinbase CEO Brian Armstrong co-founded NewLimit, a biotech startup exploring genetic rejuvenation that raised over $130 million this year.
